Libtayo Development Program News Today

/PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival                                                                         �...

FDA Approves Libtayo® as Monotherapy for Advanced NSCLC Search jobs Subject: FDA Approves Libtayo     Regeneron and Sanofi received U.S. FDA approval for Libtayo® (cemiplimab-rwlc, an PD-1 inhibitor) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%), %), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates ...

Sanofi: FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50% N=356 a 14 months Median (95% CI) b Based on stratified proportional hazards model An additional prespecified analysis was performed in 563 patients with proven PD-L1 expression of =50%, according to the FDA-approved assay, and is described in the updated labeling of the FDA-approved assay (and also recently published (https://www.sanofi.com/...

/PRNewswire/ -- Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics...